Liabilities / Assets
87th percentile
Higher debt load relative to assets than 87% of similar nonprofits.
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
Liabilities / Assets
87th percentile
Higher debt load relative to assets than 87% of similar nonprofits.
Liabilities / Revenue
69th percentile
Higher debt load relative to revenue than 69% of similar nonprofits.
Net Margin
48th percentile
Higher net margin than 48% of similar nonprofits.
Top Officer Pay
Score unavailable
This filing does not contain officer compensation rows.
Asset Growth
72nd percentile
Faster asset growth than 72% of similar nonprofits.
Revenue Growth
21st percentile
Faster revenue growth than 21% of similar nonprofits.
Assets
Up$18,858
Up $3,014 (+19%) from 2011
Net Assets
Up$10,420
Up $6,913 (+197%) from 2011
Liabilities
Down$8,438
Down $3,899 (-32%) from 2011
Revenue
Down$408,049
Down $120,465 (-23%) from 2011
Expenses
Down$401,136
Down $202,060 (-33%) from 2011
Net Income
Up$6,913
Up $81,595 (+109%) from 2011
This 2012 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.
The hhv-6 foundation is a non-profit entity founded to encourage scientific exchange between scientists and to provide pilot grants for promising scientific and clinical research.the first priority of the foundation is to provide information and reagents to investigators who are interested in studying hhv-6. We maintain a repository of reagents including monoclonal antibodies,cosmids, hybridomas, cell lines and viral lysates that are donated by investigators around the world, and we make these valuable research materials available to researchers free of charge. We arrangecollaborations between investigators, host conferences and coordinate initiatives among investigators to develop consensus on issues relating to hhv-6. We attend conferences in the field of neurology and stem cell transplants to provide investigators with information about hhv-6, and to encourage clinical research.another important priority for the foundation is to encourage efforts to find antiviral compounds that are
No mirrored PDF or thumbnail assets are attached yet.
Displayed year
2012 • Form 990Summary only. Only limited summary data is available for this year.